<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03589027</url>
  </required_header>
  <id_info>
    <org_study_id>PK22</org_study_id>
    <nct_id>NCT03589027</nct_id>
  </id_info>
  <brief_title>Darunavir and Rilpivirine Interactions With Levonorgestrel Implant</brief_title>
  <acronym>DRIVE-2</acronym>
  <official_title>A Pharmacokinetic Evaluation of Levonorgestrel Implant in HIV-Infected Women on Darunavir Versus Rilpivirine-based Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetic properties of Rilpivirine and Darunavir when&#xD;
      used in combination with Levonorgestrel&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the benefits of hormonal contraceptives, significant drug-drug interactions (DDIs)&#xD;
      with some antiretroviral therapies (ART) represent a barrier to effective family planning&#xD;
      methods for HIV-infected women. It is therefore critical to generate data on the combined use&#xD;
      of hormonal contraceptives and ART. This study is a prospective, non-randomized, open-label,&#xD;
      parallel, two-group, sparse-sampling pharmacokinetic (PK) study to describe levonorgestrel&#xD;
      (LNG) PK parameters in two treatment groups (rilpivirine or darunavir- based ART) in 60 HIV-1&#xD;
      infected women. The primary endpoint is the comparison of the mean LNG concentrations at&#xD;
      month 6 between the rilpivirine or darunavir treatment groups versus historical controls.&#xD;
      This study will provide information on effective ART options for HIV positive women who opt&#xD;
      for the contraceptive implant as a family planning method of choice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">August 7, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective, non-randomized, open-label, parallel, two-group, sparse-sampling pharmacokinetic (PK) study to describe levonorgestrel (LNG) PK parameters in two treatment groups (Rilpivirine or Darunavir- based ART) in 60 HIV-1 infected women.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levonorgestrel concentrations: Change in mean levonorgestrel (LNG) concentrations</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison of the mean levonorgestrel (LNG) concentrations at month 6 between the rilpivirine (RPV) or darunavir (DRV) treatment groups versus historical controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean rilpivirine concentration</measure>
    <time_frame>12 months</time_frame>
    <description>Rilpivirine mean concentration change prior to implant placement and then over the duration of the study time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean darunavir concentration</measure>
    <time_frame>12 months</time_frame>
    <description>Darunavir mean concentration change prior to implant placement and then over the duration of the study time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Any signs and symptoms related to hormone exposure, including abnormal vaginal bleeding and local or systemic adverse events observed during the study period in both study groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV-1-infection</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Rilpivirine arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be administered oral rilpivirine 25mg once daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darunavir arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be administered oral darunavir/ritonavir 600/100mg twice daily together with the rest of their oral antiretroviral combination plus a levonorgestrel two-rod subdermal implant (75mg/rod) through out the study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel two rod sub-dermal implant</intervention_name>
    <description>Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally</description>
    <arm_group_label>Darunavir arm</arm_group_label>
    <arm_group_label>Rilpivirine arm</arm_group_label>
    <other_name>Levonorgestrel</other_name>
    <other_name>Jadelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilpivirine</intervention_name>
    <description>Oral ripilvirine 25mg once daily</description>
    <arm_group_label>Rilpivirine arm</arm_group_label>
    <other_name>Edurant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir+Ritonavir</intervention_name>
    <description>Oral DRV/r 600/100mg twice daily</description>
    <arm_group_label>Darunavir arm</arm_group_label>
    <other_name>DRV/r</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the participant has been informed of all pertinent aspects of the study.&#xD;
&#xD;
          2. Participants who are willing and able to comply with scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures.&#xD;
&#xD;
          3. Women age 18 years to 45 years&#xD;
&#xD;
          4. Diagnosed with HIV infection&#xD;
&#xD;
          5. Medically eligible for the LNG subdermal implant as a contraceptive method based on&#xD;
             the WHO Medical Eligibility Criteria for Contraceptive Use11&#xD;
&#xD;
          6. Receiving EFV- or LPV/r-based ART for a minimum of 1 year&#xD;
&#xD;
          7. If not abstinent, must agree to use an effective non-hormonal method of contraception&#xD;
             for the duration of the study including male and female condoms or the copper-T&#xD;
             intrauterine device.&#xD;
&#xD;
          8. Participants must have a negative urine pregnancy test at entry and report no&#xD;
             unprotected sex since the last menstrual period or in the last two weeks.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HIV RNA greater than 50 copies/mL at the screening visit&#xD;
&#xD;
          2. CD4 count below 200 cells/mm3 at the screening visit&#xD;
&#xD;
          3. History of virologic failure on the current regimen (two consecutive viral load&#xD;
             results equal to or greater than 400 copies/mL)&#xD;
&#xD;
          4. Serum hemoglobin less than 9.0 g/dl at screening&#xD;
&#xD;
          5. Elevations in serum levels of alanine transaminase (ALT) above 5 times the upper limit&#xD;
             of normal&#xD;
&#xD;
          6. Elevations in serum creatinine above 2.5 times the upper limit of normal&#xD;
&#xD;
          7. Use of drugs known to be contraindicated with LNG, RPV (for women taking EFV-based&#xD;
             ART), or DRV (for women taking LPV-based ART) within 30 days of study entry. Due to&#xD;
             the dynamic nature of drug interactions related to antiretroviral therapy, the study&#xD;
             team will review all concomitant medications at screening based on the US Department&#xD;
             of Health and Human Services drug interaction table 14 and the University of Liverpool&#xD;
             HIV drug interaction tables (www.hiv-druginteractions.org)&#xD;
&#xD;
          8. Currently pregnant or postpartum &lt;30 days at study entry.&#xD;
&#xD;
          9. Breastfeeding women within 6 months of delivery.&#xD;
&#xD;
         10. Patients with a history of hypersensitivity to LNG implant, undiagnosed vaginal&#xD;
             bleeding, diagnosed or suspected sex hormone dependent neoplasia, benign or malignant&#xD;
             liver tumor, or thromboembolic disease.&#xD;
&#xD;
         11. Presence of any active clinically significant disease or life-threatening disease&#xD;
             that, in the investigator's opinion, would compromise the subject's safety or outcome&#xD;
             of the study.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Lamorde, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Senior Research Manager</last_name>
    <phone>0704817590</phone>
    <email>sokoboi@idi.co.ug</email>
  </overall_contact>
  <location>
    <facility>
      <name>Infectious Diseases Institue</name>
      <address>
        <city>Kampala</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Research Manager</last_name>
      <phone>0392878652</phone>
      <email>sokoboi@idi.co.ug</email>
    </contact>
    <investigator>
      <last_name>Mohammed Lamorde, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kimberley Scarsi, PharmD,MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Chappell, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saye Khoo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline Byakika, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin Darin, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shadia Nakalema, MBChB, DTM&amp;H</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Walimbwa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Kaboggoza, BPharm</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 29, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>March 26, 2019</last_update_submitted>
  <last_update_submitted_qc>March 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makerere University</investigator_affiliation>
    <investigator_full_name>Infectious Diseases Institute</investigator_full_name>
    <investigator_title>Head of Department, Prevention Care and Treatment Infectious Diseases Institute, Makerere University College of Health Sciences</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

